Three-year oral clodronate treatment does not impair mineralization of newly formed bone - A histomorphometric study

Calcified Tissue International

Volumn 77, Issue 2, 2005, Pages 84-90

  Saarto, T ^a   Taube, T ^b   Blomqvist, C ^a   Vehmanen, L ^a   Elomaa, I ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Oy Leiras Finland Ab   (Finland)

Author keywords

Bisphosphonates; Bone density; Bone histomorphometry; Bone turnover; Mineralization

Indexed keywords

ANTIESTROGEN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BONE BIOPSY; BONE EROSION; BONE MINERAL; BONE MINERALIZATION; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; HYPERPARATHYROIDISM; ILIAC BONE; LONG TERM CARE; MORPHOMETRICS; OSSIFICATION; OSTEOCLAST; OSTEOID; OSTEOLYSIS; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TRABECULAR BONE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CALCIFICATION, PHYSIOLOGIC; CHEMOTHERAPY, ADJUVANT; CLODRONIC ACID; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; ILIUM; METHOTREXATE; MIDDLE AGED;

EID: 27144484458     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-004-0262-2     Document Type: Article

References (27)

1. I Elomaa C Blomqvist P Gröhn L Porkka AL Kairento K Selander C Lamberg-Allardt T Holmstrom 1983 Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases Lancet 1 146 149
2. B Kristensen B Ejlertsen M Groenvold S Hein H Loft HT Mouridsen 1999 Oral clodronate in breast cancer patients with bone metastases: a randomized study J Intern Med 246 1 67 74
3. AH Paterson TJ Powles JA Kanis E McCloskey J Hanson S Ashley 1993 Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer J Clin Oncol 11 59 65
4. PF Conte J Latreille L Mauriac F Calabresi R Santos D Campos J Bonneterre G Francini JM Ford 1996 Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial J Clin Oncol 14 2552 2559
5. GN Hortobagyi RL Theriault A Lipton L Porter D Blayney C Sinoff H Wheeler JF Simeone JJ Seaman RD Knight M Heffernan K Mellars DJ Reitsma 1998 Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate J Clin Oncol 16 2038 2044
6. RL Theriault A Lipton GN Hortobagyi R Leff S Gluck JF Stewart S Costello I Kennedy J Simeone JJ Seaman RD Knight K Mellars M Heffernan DJ Reitsma 1999 Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial J Clin Oncol 17 846 854
7. R Hultborn S Gundersen S Ryden E Holmberg J Carstensen UB Wallgren S Killany L Andreassen G Carlsson N Fahl T Hatschek HH Sommer Y Hessman B Hornmark-Stenstam S Johnsborg R Klepp R Laino LG Niklasson CM Rudenstam A Sundbeck M Soderberg G Tejler 1999 Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study Anticancer Res 19 4C 3383 3392
8. LS Rosen D Gordon M Kaminski LS Rosen D Gordon M Kaminski A Howell A Belch J Mackey J Apffelstaedt M Hussein RE Coleman DJ Reitsma JJ Seaman BL Chen Y Ambros 2001 Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial Cancer J 7 5 377 387
9. I Diel E Solomayer SD Costa C Gollan R Goerner D Wallwiener M Kaufmann G Bastert 1998 Reduction in new metastases in breast cancer with adjuvant clodronate treatment N Engl J Med 339 157 363
10. T Powles S Paterson JA Kanis E McCloskey S Ashley A Tidy K Rosenqvist I Smith L Ottestad S Legault M Pajunen A Nevantaus E Mannisto A Suovuori S Atula J Nevalainen L Pylkkanen 2002 Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer J Clin Oncol 20 15 3219 3224
11. T Saarto C Blomqvist P Virkkunen I Elomaa 2001 Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial J Clin Oncol 19 1 10 17
12. T Saarto C Blomqvist M Välimäli P Mäkelä I Elomaa 1997 Chemical castration induced by adjuvant CMF chemotherapy causes a rapid bone loss which is reduced by clodronate. A randomised study in pre-menpausal breast cancer women J Clin Oncol 15 1341 1347
13. L Vehmanen T Saarto I Elomaa P Mäkelä M Välimäki C Blomqvist 2001 Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment" Eur J Cancer 37 18 2373 2378
14. T Saarto C Blomqvist M Välimäki P Makela S Sarna I Elomaa 1997 Clodronate improves bone mineral density in postmenopausal breast cancer women treated with adjuvant antiestrogens Br J Cancer 75 602 605
15. RG Russell MJ Rogers 1999 Bisphosphonates: from the laboratory to the clinic and back again Bone 25 1 97 106
16. JR Green P Clezardin 2002 Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis Am J Clin Oncol 25 6 Suppl 1 S3 S9
17. EV McCloskey JA Yates MN Beneton J Galloway S Harris JA Kanis 1987 Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man Bone 8 Suppl 1 S35 41
18. T Taube I Elomaa C Blomqvist MN Beneton JA Kanis 1993 Comparative effects of clodronate and calcitonin on bone in metastatic breast cancer: a histomorphometric study Eur J Cancer 29A 12 1677 1681
19. BF Boyce L Smith I Fogelman E Johnston S Ralston IT Boyle 1994 Focalosteomalacia due to low-dose diphosphonate therapy in Paget's disease Lancet 1 8381 821 824
20. BB Adamson SJ Gallacher J Byars SH Ralston IT Boyle BF Boyce 1993 Mineralisation defects with pamidronate therapy for Paget's disease Lancet 342 8885 1459 1460
21. SJ Wimalawansa 1995 Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study Am J Med 99 1 36 42
22. SL Ruggiero B Mehrotra TJ Rosenberg SL Engroff 2004 Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases J Oral Maxillofac Surg 62 5 527 534
23. JE Aarola AR Johnson JA Kanis BA Oakley P O'Higgins SK Paxton 1992 An automated method for the analysis of trabecular bone structure. Comput Biomed Res 25 1 16
24. T Saarto C Blomqvist J Risteli L Risteli I Elomaa 1998 Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and postmenopausal non metastatic breast cancer patients Br J Cancer 78 2 240 245
25. B Zegels R Eastell RG Russell D Ethgen I Roumagnac J Collette JY Reginster 2001 Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis Bone 28 108 112
26. SL Greenspan S Holland L Maitland-Ramsey M Poku A Freeman W Yuan U Kher B Gertz 1996 Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy Proc Assoc Am Phys 108 3 230 238
27. PD Delmas MC Chapuy C Vignon S Charhon D Briancon C Alexandre C Edouard PJ Meunier 1982 Long term effects of dichloromethylene diphosphonate in Paget's disease of bone J Clin Endocrinol Metab 54 4 837 844